NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.
Transfection Reagent for Calu-3 Cells (Lung Carcinoma Cells, HTB-55)
Proprietary cationic lipids formulation
High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
Effective and robust intracellular delivery
Kit includes Transfection Enhancer reagent
Produces consistent results, lot-to-lot, plate-to-plate, and well-to-well
Work in the presence of serum
A proven reagent for establishing stable cell lines
Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
Download PowerPoint presentation for Calu-3 cells transfection kit: [PPT]
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 90% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems Transfection Protocol: [PDF]
Download MSDS: [PDF]
Calu-3 Cell Line:
Despite the highly preventable nature of lung cancer, it remains the second most common cancer in the world and has higher mortality rates than colon, breast, and prostate cancers combined. Lung cancer is continuously listed among the leading causes of death around the globe, and further research is needed to find a definite cure. Preclinical research is an essential element for understanding tumor growth dynamics and its interaction with the immune system. Originally derived from the lung tissue of a 25-year-old Caucasian male with adenocarcinoma, the tumorigenic Calu-3 cell line has an epithelial cell morphology and is a suitable host for studies related to lung cancer as well as for other biomedical applications. This patient was treated with Cytoxan, Bleomycin, and Adriamycin before removal of cells. Altogen Biosystems provides efficient lipid-based transfection reagent kits for the Calu-3 lung cancer cell line.
Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into Calu-3 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).
Figure 2. Protein expression of Lamin A/C in Calu-3 cells. DNA plasmid expressing Lamin A/C or siRNA targeting Lamin A/C were transfected into Calu-3 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems provides pre-optimized transfection kits and electroporation products for life science research. Transfection products are developed for individual cancer cell line and transfection protocols are optimized to enable high transfection efficiency of biomolecules. Altogen Biosystems developed in vivo delivery products for small animal research, mouse and rat targeted tissue delivery: liver targeted, pancreas targeted, kidney targeted, PEG-Liposome-, Nanoparticle-, Lipid-, and Polymer-based in vivo transfection kits. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of biomolecules. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6401)
- 1.5 ml (Catalog #6402)
- 1.5 ml CRISPR (Catalog #2124)
- 8.0 ml (Catalog #6403)